BioSpace News Archive

Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on recent developments in its business.

Iridex Corporation, a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the Company plans to participate in the upcoming 34th Annual Roth Conference.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), today announced that the Company will present a poster highlighting the characterization of potent and selective next-generation EGFR inhibitors at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

BioInvent International AB announces that data regarding the anti-TNFR2 drug candidate BI-1808, currently in clinical development, will be presented at the forthcoming annual meeting of the American Association for Cancer Research in April 2022.

Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that is has executed a U.S. settlement agreement with AbbVie (NYSE: ABBV) that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira®.

Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will present data across five distinct immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orleans from April 8-13, 2022.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022.

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and best-in-class allosteric therapies targeting regulatory sites on proteins referred to as “natural hotspots,” today announced it will present additional pre-clinical data on the company’s CBL-B program in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022.

CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer cell-based cancer therapies, today announced that the company will present preclinical data from its FLT3 CAR-NK cell program for acute myeloid leukemia and its TRACK-NK™ program for non-small cell lung cancer at the American Association for Cancer Research (AACR) Annual Meeting.